CPX-351 Plus Quizartinib
A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 52 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Chemotherapy, Tyrosine Kinase (TK) Inhibitor
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1523
- NCT Identifier
- NCT04128748
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.